This randomized clinical trial examines data via prespecified analysis to evaluate the bleeding risk of the novel factor XI inhibitor abelacimab vs rivaroxaban in patients with atrial fibrillation (AF) according to their age (<75 vs ≥75 years).
JAMA Cardiology published a clinical update in Cardiology on 01 Mar 2026.
The item focuses on Abelacimab vs Rivaroxaban in Older Individuals With AF.
Review the original article for the full source wording and details.